Sean D Carlin
Overview
Explore the profile of Sean D Carlin including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
37
Citations
1067
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Makvandi M, Samanta M, Martorano P, Lee H, Gitto S, Patel K, et al.
Commun Biol
. 2022 Nov;
5(1):1260.
PMID: 36396952
Astatine-211-parthanatine ([At]PTT) is an alpha-emitting radiopharmaceutical therapeutic that targets poly(adenosine-diphosphate-ribose) polymerase 1 (PARP1) in cancer cells. High-risk neuroblastomas exhibit among the highest PARP1 expression across solid tumors. In this study,...
2.
Krebs S, Grommes C, McDevitt M, Carlin S, ODonoghue J, Graham M, et al.
Eur J Nucl Med Mol Imaging
. 2022 Mar;
49(6):2102.
PMID: 35266033
No abstract available.
3.
Krebs S, Grommes C, McDevitt M, Carlin S, ODonoghue J, Graham M, et al.
Eur J Nucl Med Mol Imaging
. 2021 Sep;
49(2):783-785.
PMID: 34498111
No abstract available.
4.
McDonald E, Pantel A, Shah P, Farwell M, Clark A, Doot R, et al.
JCI Insight
. 2021 Apr;
6(8).
PMID: 33884961
BACKGROUND[18F]FluorThanatrace ([18F]FTT) is a radiolabeled poly (adenosine diphosphate-ribose) polymerase inhibitor (PARPi) that enables noninvasive quantification of PARP with potential to serve as a biomarker for patient selection for PARPi therapy....
5.
Alexander E, Pantel A, Carlin S, Beckmann N, Mick R, Pryma D, et al.
J Vasc Interv Radiol
. 2020 Nov;
31(12):2007-2013.e1.
PMID: 33143997
Purpose: To evaluate total blood radioactivity (BR) after SIR-Spheres yttrium-90 (Y) radioembolization and differences in BR based on delivery method. Materials And Methods: Twenty participants with hepatic metastases undergoing first...
6.
McDonald E, Doot R, Young A, Schubert E, Tchou J, Pryma D, et al.
J Nucl Med
. 2019 Dec;
61(5):665-670.
PMID: 31836680
The σ receptor is a potential in vivo target for measuring proliferative status in cancer. The feasibility of using -(4-(6,7-dimethoxy-3,4-dihydroisoquinolin-2(1)-yl)butyl)-2-(2-F-fluoroethoxy)-5-methylbenzamide (F-ISO-1) to image solid tumors in lymphoma, breast cancer, and...
7.
Lobatto M, Binderup T, Robson P, Giesen L, Calcagno C, Witjes J, et al.
Bioconjug Chem
. 2019 May;
31(2):360-368.
PMID: 31095372
Nanotherapy has recently emerged as an experimental treatment option for atherosclerosis. To fulfill its promise, robust noninvasive imaging approaches for subject selection and treatment evaluation are warranted. To that end,...
8.
Makvandi M, Lee H, Puentes L, Reilly S, Rathi K, Weng C, et al.
Mol Cancer Ther
. 2019 May;
18(7):1195-1204.
PMID: 31072830
Alpha-emitters can be pharmacologically delivered for irradiation of single cancer cells, but cellular lethality could be further enhanced by targeting alpha-emitters directly to the nucleus. PARP-1 is a druggable protein...
9.
Alavi A, Carlin S, Werner T, Al-Zaghal A
Mol Imaging Biol
. 2019 Jan;
21(5):808-811.
PMID: 30675688
No abstract available.
10.
McKnight B, Kuda-Wedagedara A, Sevak K, Abdel-Atti D, Wiesend W, Ku A, et al.
Sci Rep
. 2018 Jun;
8(1):9043.
PMID: 29899472
Tumor resistance to treatment paved the way toward the development of single agent drugs that target multiple molecular signatures amplified within the malignancy. The discovered crosstalk between EGFR and HER3...